Arcturus Therapeutics(US:ARCT) ZACKSยท2024-11-07 23:57Company Performance - Arcturus Therapeutics reported a quarterly loss of $0.26 per share, significantly better than the Zacks Consensus Estimate of a loss of $0.70, representing an earnings surprise of 62.86% [1] - The company posted revenues of $41.67 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 15.23% and down from $45.14 million a year ago [2] - Over the last four quarters, Arcturus has surpassed consensus EPS estimates four times and topped consensus revenue estimates two times [2] Stock Movement and Outlook - Arcturus Therapeutics shares have declined approximately 41.9% since the beginning of the year, contrasting with the S&P 500's gain of 24.3% [3] - The company's earnings outlook will be crucial for future stock performance, with current consensus EPS estimate at $0.28 on revenues of $81.28 million for the coming quarter [4][7] - The estimate revisions trend for Arcturus is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Arcturus belongs, is currently ranked in the top 36% of over 250 Zacks industries, suggesting a favorable industry outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Arcturus's stock performance [5]